Phaseline

Companies › Pell Bio-Med Technology

Pell Bio-Med Technology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PL001
CD19-targeted chimeric antigen receptor T-cell (CAR-T)
CD19Phase 1Diffuse Large B Cell LymphomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05326243PL001Phase 1Diffuse Large B Cell LymphomaOncologyDec 2026

Targets

CD19 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.